Home page > Quality health systems and services | Medicines, health technology and health information

technology


Please find all related articles below.



Added therapeutic value of medicines: EPHA/Wemos event in the European Parliament


On 15 July 2015 EPHA and Wemos hosted an event in the Members’ Salon at the European Parliament to highlight the issue of added therapeutic value (ATV) in medicines. Several studies carried out at EU member state level indicate that the majority of medicines authorised for use have little-to-no ATV in comparison with existing treatments. This means that public money is being spent on new, costly medicines which have limited ATV, whilst also using up resources which might otherwise be (...)
28/08/2015

What future role for health literacy in Europe?


Public health is not just about human diseases, healthcare services or cross-border pandemics. Most of all, health is about people. Giving wider attention to the individual also fits perfectly with the European 2020 vision of ’smart, inclusive and sustainable’ growth for a healthier EU, as highlighted at a recent meeting on ’health literacy in Europe’ organised by STOA - European Parliament Science and Technology Options Assessment - on 1 July 2015. People are used (...)
03/08/2015

General Data Protection Regulation - how to reconcile ethical and business concerns?


An event organised by the CEPS on 13 May 2015 provided an update of the status quo of the General Data Protection Regulation (GDPR) and presented issues under discussion during the Trilogue negotiations. Although the principal focus lay on stimulating dialogue between regulators and SMEs/start-ups, the debate also touched upon some health-related issues such as the development of eHealth as part of the Digital Single Market, and it brought up ethical questions related to the potential uses (...)
31/05/2015

e/mHealth success depends on civil society input and endorsement


Unsurprisingly, mHealth was a hotly debated topic during the 2015 eHealth Week hosted by the Latvian Council Presidency. In addition to the official conference programme, where the mHealth summit uncovered some of the latest developments in this area, the European Commission also organised a stakeholder meeting including industry and civil society representatives to determine the appropriate level of regulation for mHealth at EU level. European Health Commissioner Vytenis Andriukaitis (...)
31/05/2015

[Press release] People living in Europe should not be left to their own devices when it comes to e/mobile Health


Brussels, 11 May 2015 – The 2015 eHealth forum, organised under the auspices of the Latvian Presidency, will discuss the next steps regarding the further roll-out of eHealth in Europe. Mobile smartphone applications in particular have propelled eHealth to centre stage in recent years. As noted in the European Commission’s Green Paper on mobile Health (mHealth) (1), 100,000 health apps are already on the market and it is estimated that 50% of smartphone owners will be using them (...)
11/05/2015

Health technology assessments and innovation in health


European Ministers of Health also adopted conclusions on innovation for the benefit of patients at a Council meeting on 1 December 2014. Ministers are calling on national governments and the European Commission to cooperate more closely on the ’life cycle approach’ for new innovative medicines and move ahead with the implementation of health technology assessment. The Council conclusions highlight the importance of early dialogue between technology developers, regulatory, (...)
18/12/2014

[Joint press release] Is President-elect Juncker erecting a smoke screen around patient safety?


28 October 2014, Brussels – MEPs, patients and the European public health community are today asking President-elect Juncker to clarify whether medical devices and health technologies will remain in the directorate for health or not. Fears over patient safety remain as Mr Juncker has so far failed to publicly clarify his ambiguous statement (1) last week to the European Parliament. Last week’s statement of the European Commission’s President-elect that the competence for (...)
28/10/2014

[Open letter to President-elect Juncker] Are we to understand that the portfolios for medical devices and health technologies will not remain with the Health Commissioner?


Further to our Joint Letter of 16 September 2014 (1) , we are contacting you again to express our gratitude for your decision (2) to move the competence for medicines and pharmaceutical products back into the hands of the European Commissioner for Health. We firmly believe that this directorate is best placed to ensure a good balance between economic and public health objectives while promoting ‘smart, sustainable and inclusive’ growth for Europe. 28 October 2014, Brussels (...)
28/10/2014

mHealth - an essential component towards integrated care


More integrated prevention and care models have long been recognised as important elements in moving towards better quality and sustainability in healthcare, in particular in view of the rising burden of non-communicable diseases and demographic change, and the complexities of multiple morbidities that this brings. By Sascha Marschang, EPHA Policy Manager for Health Systems and Milena Richter, Senior Director European Public Affairs, Sanofi. While healthcare systems move towards (...)
01/09/2014

[EPHA response] mHealth Green Paper consultation


22 July 2014 - Following in-depth discussions with members, EPHA responded to the European Commission’s public consultation on its Green Paper on mobile health (mHealth) in early July. In its response, EPHA emphasises that mHealth development should not only be seen as a way to gain cost efficiencies, but that relevant solutions - including smartphone applications - must first and foremost aim to bring concrete benefits for different types of end users including patients and health (...)
25/07/2014